Vermont has the second lowest state fatality rate in the US (147.9 per 100K; Hawaii 113.5/100K). Mississippi (465.6/100K) and ...

While the outlook for vaccines in the US looks bleak under Trump's administration, the UK is pressing ahead with securing its ...

The health and human services secretary has repeatedly claimed children need dozens more vaccines than they actually do.

Vaxart's (NASDAQ:VXRT) shares rose following the positive results from an early-stage trial of its new oral pill vaccine for norovirus, a more advanced version compared to its first-generation ...

Vaxart CEO Steven Lo stated that the company believes its second-generation norovirus oral pill vaccine candidate "has the potential to provide first-in-class or best-in-class protection" against ...

In addition to norovirus, the company is developing oral vaccines for coronavirus, influenza, HPV (therapeutic), and other indications. Currently, VXRT is trading at $0.43 up by 3.49 percent on ...

Norovirus, the leading cause of viral gastroenteritis, causes more than 700 million infections each year and can sometimes be deadly, especially in young children, older adults, and ...

Vaccine-In-A-Pill For Norovirus, The Infamous Winter Bug, Performs Well In Early Trials The trial targeted older adults, who are at risk of serious complications from the infection.

Norovirus: Scientists May Finally Be on to a Vaccine Respiratory viruses are getting all the attention, but the stomach bug – norovirus, formally – has also made a big impact this winter.

“We are pleased to initiate a Phase 1 trial for our oral bivalent norovirus vaccine, delivered in a pill formulation, which will seek to demonstrate improved immune responses of our second ...

The participants were randomly assigned to get either a placebo (22) or a low (16), medium (16), or high (11) dose of the vaccine VXA-G1.1-NN, which targets one genotype of norovirus.

WHILE norovirus still circulates at high levels, a new pill designed to protect against the winter vomiting bug has been undergoing trials. Just two weeks ago there was a record number of patients … ...